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Moxifloxacin against exacerbations of brochitis 1505indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic
eradication or presumed eradication was also similar in the two treatment groups:
92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the
most common drug-related adverse event in each treatment group. The rate of
discontinuation because of adverse events was very low (p2%). In conclusion, a
5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day
course of levofloxacin in the treatment of patients with AECB. The short treatment
duration with moxifloxacin may have compliance advantages over other currently
used therapies in the ‘real-life’ clinical setting.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Acute exacerbations of chronic bronchitis (AECB)
present as a worsening of respiratory symptoms,
and can be precipitated by a variety of factors
including air pollutants, allergens, viruses and, in
50–60% of cases, by bacterial infection.1,2 Chronic
bronchitis and accompanying exacerbations are
associated with a high socio-economic burden.
The direct annual cost in the USA of treating AECB
has been calculated at $1.6 billion per year, of
which $1.5 billion is spent on hospitalizations.3
Thus, new therapies that enable AECB patients to
be treated primarily on an outpatient basis are
likely to be associated with substantial cost
savings.
A recent meta-analysis of large, placebo-con-
trolled trials suggests a benefit of antimicrobial
therapy in AECB, particularly in patients categor-
ized as having type I symptoms (i.e., increased
dyspnea, sputum volume, and sputum purulence).4
Ideally, choice of antimicrobial therapy should be
based on confirmed identification and susceptibility
of the causative pathogen. However, microbiology
test results are rarely available to guide initial
therapy, which is consequently often empiric. This
approach requires agents with activity against the
bacterial pathogens most likely to be encountered,
namely Haemophilus influenzae, Streptococcus
pneumoniae, and Moraxella catarrhalis.1,2,5 Anti-
microbial resistance has developed rapidly over the
last 20 years in each of these species, and local
resistance patterns should also be taken into
account when selecting appropriate therapy.
Fluoroquinolones have been considered as im-
portant options in facing growing bacterial resis-
tance. Levofloxacin, the S-() isomer from the
racemic mixture known as ofloxacin6; and moxi-
floxacin, a newer 8-methoxyquinolone, have shown
enhanced in vitro activity against bacterial patho-
gens commonly implicated in respiratory tract
infections, as well as atypical pathogens (e.g.,
Mycoplasma pneumoniae).6,7 The aim of the pre-
sent study was to compare the clinical efficacy andsafety of oral moxifloxacin 400mg once daily for 5
days with oral levofloxacin 500mg once daily for 7
days in the treatment of patients with AECB.Methods
Study design
This was a prospective, multinational, double-
blind, randomized, controlled, parallel-group clin-
ical study designed to compare 5-day oral moxi-
floxacin therapy with 7-day oral levofloxacin
therapy in the treatment of AECB. Thirty-four
centers in five Latin American countries (Argentina,
Brazil, Colombia, Mexico, and Peru) participated.
Patient selection
Adult patients (X18 years of age) were eligible for
inclusion in the study if they had a diagnosis of
chronic bronchitis (history of cough and sputum on
most days during at least 3 consecutive months and
for more than 2 successive years), with exacerba-
tion within the previous 14 days characterized by
increased cough, increased sputum production with
changes in color and consistency, and mild-to-
moderate dyspnea. Patients were not included if
they had received recent antibiotic therapy, had
other lower respiratory tract illnesses (e.g., pneu-
monia, bronchiectasis, tuberculosis, cystic fibrosis,
or pulmonary malignancy) detected clinically and
by X-ray, were pregnant or lactating, had severe
hepatic, cardiac, or renal impairment, or concomi-
tant serious illness, had a history of allergy to
fluoroquinolones, or had recently participated in
another clinical trial.
Antibacterial therapy
Patients were randomized in groups of four to
either moxifloxacin 400mg once daily for 5 days or
levofloxacin 500mg once daily for 7 days. Both
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Germany). Blinding was ensured by placing either
moxifloxacin 400mg tablets or placebo tablets
inside a capsule of identical appearance to that of
levofloxacin 250mg. Since levofloxacin dose con-
sisted of two 250mg capsules, the patients in the
moxifloxacin group received for each dose one
placebo capsule and one active moxifloxacin
capsule during the first 5 days, and two placebo
capsules for the remaining 2 days to maintain
blinding.Clinical assessments
All patients attended four visits on an outpatient
basis. Evaluations were performed at entry (base-
line), 3–5 days after starting therapy (on-therapy
evaluation), 1–3 days after completion of therapy
(end-of-therapy), and 7–14 days after completion
of therapy (test of cure; primary efficacy variable).
On-therapy visit could be conducted by telephone
if the patient was doing well. At each visit, clinical
signs and symptoms were assessed and compared to
baseline, compliance with medication was checked
by a medication count, and concomitant medica-
tion were recorded. Clinical response was classified
as (i) resolution (total resolution of signs and
symptoms related to the acute exacerbation to
such an extent that no additional or alternative
therapy was necessary), (ii) failure (persistence or
worsening of all or most of the signs and symptoms
related to the acute exacerbation, or the need for
hospitalization or other antibacterial), or (iii)
indeterminate (no evaluation possible). If clinical
failure was documented, a sputum sample was
obtained and alternate medication prescribed.Bacteriologic assessments
Sputum samples were obtained at baseline, at test-
of-cure visit (if material was available), and in
cases of clinical failure. Cultures were then
performed locally and isolates forwarded to a
central laboratory. To be considered evaluable,
sputum samples were scored according to the
Murray–Washington Group 5 Score System. The
susceptibility of bacterial isolates toward moxiflox-
acin and levofloxacin, as well as ampicillin,
clarithromycin and cefuroxime, was tested using
E-test, following manufacturers’ guidelines.
Patients who provided a bacteriologically posi-
tive baseline sputum sample were included in the
evaluation of bacteriologic response. Because many
patients were unable to provide sputum samples at
resolution, bacteriologic response was judged pre-sumptively. Bacteriologic response was classified as
(i) presumed eradication (clinical cure in the
absence of a repeat sputum culture), (ii) docu-
mented eradication (absence of original pathogen
in culture of sputum sample taken 1–2 weeks post-
therapy), (iii) presumed persistence (clinical fail-
ure in the absence of a repeat sputum culture), (iv)
persistence (presence of original pathogen in
culture of sputum sample taken 1–2 weeks post-
therapy), (v) superinfection (isolation of a different
pathogen during therapy in a symptomatic patient),
or (iv) indeterminate (no evaluation possible).Safety assessments
At each assessment after signing the informed
consent, clinical and laboratory adverse events
were recorded. Severity (mild, moderate, severe),
threatening to life or not, relationship to study drug
(possible, probably, remote, none), and outcome
were monitored until resolution. Clinical laboratory
parameters (hematology, urinalysis, and chemistry)
were performed on blood and urine samples
obtained pre-therapy and at the post-therapy
visits.Statistical analyses
The primary efficacy variable was the clinical
outcome at the test-of-cure visit in the valid per-
protocol population. The primary aim of the study
was to reject the null hypothesis, that a 5-day
therapy with moxifloxacin 400mg OD for 5 days was
more than 10% less effective than a 7-day therapy
with levofloxacin 500mg OD. For the difference in
clinical success rates, a 95% confidence interval
(95% CI, moxifloxacin minus levofloxacin) was
calculated using Mantel–Haenszel weights. For
moxifloxacin to be considered not less effective
than levofloxacin, the lower limit of this confidence
interval had to be greater than –10%. The same
approach was used for the bacteriological response
at test-of-cure visit in the efficacy-valid or per-
protocol population and for the clinical and
bacteriological outcomes in the intention-to-treat
population. The two treatment groups were as-
sessed for comparability in their demographic and
other baseline characteristics by standard statisti-
cal methods. Safety analysis included tabulations of
type and frequency of all adverse events. All
laboratory data were analyzed using descriptive
statistics including identification of cases outside of
normal ranges.
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Patient sorting
Five hundred and sixty-three patients were en-
rolled in the study: 279 received moxifloxacin and
284 received levofloxacin. One patient in each
group was excluded from the intention-to-treat/
safety analysis for not receiving study medication.
Four hundred and thirty seven patients met the
pre-defined criteria for the population (221 in the
moxifloxacin group and 216 in the levofloxacin
group). The most common reasons for exclusion
from the per-protocol analysis were violation of
entry criteria (moxifloxacin 25; levofloxacin 40) andTable 1 Demographics and baseline medical characteris
Moxifl
Demographics
Age, years, mean7SD 5971
Sex, no. male/female 110/1
Race, n (%)
Mestizo 143 (
Caucasian 72 (3
Other/not reported 6 (2.7
Pathological findings on chest X-ray, n (%) 46 (2
Onset of current AECB episode, n (%)
0o4 days prior to therapy 27 (1
4o7 days prior to therapy 56 (2
X7 days prior to therapy 138 (
History of smoking, n (%)
Never smoked 68 (3
Past smoker 104 (
Current smoker 49 (2
Average no. of cigarettes/dayy, mean7SD 17.92
Duration of smokingz, years, mean7SD 32.73
Clinical signs and symptoms
Increased purulent/mucopurulent sputum,
n (%)
221 (
Cough, n (%)
Mild 23 (1
Moderate 149 (
Severe 49 (2
Dyspnea, n (%)
Mild 78 (3
Moderate 143 (
Fever, n (%) 37 (1
Mixed race (Caucasian and indigenous population).
yFor smokers.
zPast and current smokers only.missing essential data (moxifloxacin 38; levoflox-
acin 32). There were 45 premature discontinuations
from the study (moxifloxacin 23; levofloxacin 22).
The most common reasons were adverse events
(moxifloxacin 5; levofloxacin 6) and lost to follow
up (moxifloxacin 6; levofloxacin 7).Demographics and baseline characteristics
Demographic data and baseline medical character-
istics for the efficacy-valid population are pre-
sented in Table 1. In both the per-protocol and
intention-to-treat populations, the two treatment
groups were comparable with respect to baselinetics: efficacy-valid population.
oxacin (n ¼ 221) Levofloxacin (n ¼ 216)
5 61715
11 110/106
64.7) 149 (69.0)
2.6) 63 (29.2)
) 4 (1.8)
0.8) 29 (13.4)
2.2) 34 (15.7)
5.3) 56 (25.9)
62.4) 126 (58.3)
0.8) 62 (28.7)
47.1) 111 (51.4)
2.2) 62 (19.9)
714.40 14.77712.02
716.59 35.22715.91
100) 216 (100)
0.4) 24 (11.1)
67.4) 152 (70.4)
2.2) 40 (18.5)
5.3) 88 (40.7)
64.7) 128 (59.3)
6.7) 37 (17.1)
ARTICLE IN PRESS
J. Urueta-Robledo et al.1508demographics and medical history/symptomatol-
ogy. In total, 184 patients in the moxifloxacin group
and 180 patients in the levofloxacin group had
concomitant medication that began before the
study treatment was initiated. Fifty-four patients
(19.4%) in the moxifloxacin group and 68 (24.0%) in
the levofloxacin group had concomitant medication
(excluding antibacterial agents) started during the
study. The majority of the concomitant medications
were drugs such as b2-selective adreno-receptor
agonists used for respiratory tract indications.Clinical response
For the per-protocol population, clinical improve-
ment was reported for 96.8% of moxifloxacin
recipients and 96.3% of levofloxacin recipients at
the end-of-therapy visit (Table 2). At the test-of-
cure visit clinical resolution (success) was achieved
in 91.0% and 94.0% of patients in the moxifloxacin
and levofloxacin groups, respectively (95% CI
7.30%, 2.29%) indicating that moxifloxacin was
not less effective than levofloxacin. This conclusion
was confirmed in the intention-to-treat population:
80.9% clinical success in the moxifloxacin group
versus 83.7% in the levofloxacin group at test-of-
cure visit (95% CI –8.95, 3.43). Likewise clinical
success was unrelated to concomitant use of
corticosteroid or coexistence of cardiopulmonary
disease (data not shown).
Both treatment groups experienced a substantial
improvement in the signs and symptoms of AECB
within the inclusion and the test-of-cure visits. The
presence of increased purulent/mucopurulent spu-
tum decreased from 100% in both groups at baseline
to 28 (12.7%) of moxifloxacin patients and 15 (6.9%)Table 2 Clinical response rates in the efficacy-valid and
Efficacy-vali
Moxifloxacin
(n ¼ 221) (%
End of therapy (1–3 days post therapy)
Improvement 214 (96.8)
Failure 5 (2.3)
Indeterminate 2 (0.9)
Test of cure (7–14 days post therapy)
Resolution 201 (91.0)
Failure 20 (9.0)
Indeterminate 0of levofloxacin patients. The proportion of patients
reporting moderate-to-severe cough decreased
from 89.6% in the moxifloxacin group and 88.9%
and levofloxacin group at baseline to 6.4% and
4.2%, respectively. The percentage of patients
experiencing moderate dyspnea also decreased
from 64.7% to 8.1% in the moxifloxacin group and
from 59.3% to 7.4% in the levofloxacin group.Bacteriologic results
Bacteria considered causative of AECB were cul-
tured from the sputum of 172 moxifloxacin patients
and 169 levofloxacin patients in the intention-to-
treat population. Of these, 267 patients (moxiflox-
acin 138; levofloxacin 129) were also valid for
efficacy and said to be microbiologically valid. In
total, 230 microbiologically valid patients had one
pathogen isolated, 36 had two, and one patient had
more than two pathogens. The spectrum of organ-
isms isolated was comparable between the two
treatment groups, and most commonly included H.
influenzae, Klebsiella pneumoniae, S. pneumoniae
and M. catarrhalis. Antimicrobial susceptibility of
isolates of these species is shown in Table 3.
Bacteriologic response at the test-of-cure visit is
summarized in Table 4. Bacteriologic success was
achieved in 92.8% of patients in the moxifloxacin
group and 93.8% of patients in the levofloxacin
group (95% CI 6.8%, 5.1%), confirming that
moxifloxacin was not less effective than levoflox-
acin in this regard. Nine patients in the moxiflox-
acin group had persistent or presumed persistent
bacteria at this visit, including three H. influenzae,
two S. pneumoniae, one Haemophilus parainfluen-
zae, two Staphylococcus aureus, one Pseudomonasintent-to-treat populations.
d population Intent-to-treat (safety)
population
)
Levofloxacin
(n ¼ 216) (%)
Moxifloxacin
(n ¼ 278) (%)
Levofloxacin
(n ¼ 283) (%)
208 (96.3) 258 (92.8) 257 (90.8)
7 (3.2) 5 (1.8) 9 (3.2)
1 (0.5) 4 (1.4) 7 (2.5)
11 (4.0) 10 (3.5)
203 (94.0) 225 (80.9) 237 (83.7)
13 (6.0) 21 (7.6) 23 (8.1)
0 11 (4.0) 7 (2.5)
21 (7.6) 16 (5.7)
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Table 3 Antimicrobial susceptibility of typical isolated pathogens, at baseline.
n MOX LEV AMP CLA CEF
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
H. in 77 0.023 0.19 0.016 0.064 0.25 6 4 12 0.5 1
K. pn 40 0.056 0.19 0.047 0.25 48 4256 24 64 2.5 12
M. ca 36 0.047 0.38 0.032 0.094 0.5 2 0.064 4 0.5 3
S. pn 29 0.094 0.25 0.38 0.75 0.016 0.5 0.032 0.5 0.016 0.38
MOX, moxifloxacin; LEV, levofloxacin; AMP, ampicillin; CLA, clarithromycin; CEF, cefuroxime. H. in, Haemophilus influenzae; K.
pn, Klebsiella pneumoniae; M. ca, Moraxella catarrhalis; S. pn, Streptococcus pneumoniae. MIC50 and MIC90 values in mg/mL.
Table 4 Bacteriologic response 7–14 days post therapy in the microbiologically valid population.
No. (%) of patients
Moxifloxacin (n ¼ 138) Levofloxacin (n ¼ 129)
Bacteriologic success 128 (92.8) 121 (93.8)
Eradication 12 (8.7) 14 (10.9)
Presumed eradication 116 (84.1) 107 (82.9)
Bacteriologic failure 10 (7.2) 8 (6.2)
Eradication+superinfection 1 (0.7) 0
Persistence 4 (2.9) 4 (3.1)
Presumed persistence 5 (3.6) 4 (3.1)
Table 5 Most common adverse events considered possibly or probably related to study drug.
Adverse event No. (%) of patients
Moxifloxacin (n ¼ 278) Levofloxacin (n ¼ 283)
Digestive tract 33 (11.9) 40 (14.1)
Nausea 12 (4.3) 16 (5.7)
Diarrhea 8 (2.9) 8 (2.8)
Body as a whole 19 (6.8) 7 (2.5)
Headache 7 (2.5) 4 (1.4)
Nervous system 10 (3.6) 10 (3.5)
Dizziness 2 (0.7) 2 (0.7)
Somnolence 3 (1.1) 2 (0.7)
Insomnia 1 (0.4) 4 (1.4)
Total 66 (23.7) 76 (26.9)
Moxifloxacin against exacerbations of brochitis 1509aeruginosa, one Burkholderia cepacia, and one K.
pneumoniae (some patients had more than one
pathogen). Levofloxacin failed to eradicate nine
bacteria from eight patients — including two H.
influenzae, one H. parainfluenzae, two P. aerugi-
nosa, one K. pneumoniae and one P. mirabilis.
There was a high correlation between bacter-
iologic and clinical success. Of 126 moxifloxacin-
treated patients classified as clinical successes, 124(98.4%) were bacteriologic successes; of 122 levo-
floxacin-treated patients classified as clinical suc-
cesses, 119 (97.5%) were bacteriologic successes.Safety
The safety population included 561 patients
(moxifloxacin 278; levofloxacin 283). The median
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treatment groups, with a range of 1–8 days in the
moxifloxacin group and 1–7 days in the levofloxacin
group. Adverse events considered possibly or
probably related to study medication were re-
ported by 66 (23.7%) patients in the moxifloxacin
group and 76 (26.9%) patients in the levofloxacin
group. The majority of drug-related adverse events
were mild in intensity, and most commonly involved
the digestive tract (Table 5). Five patients in the
moxifloxacin group and six patients in the levo-
floxacin group prematurely discontinued treatment
because of adverse events, and eight moxifloxacin-
treated patients and six levofloxacin-treated pa-
tients required hospitalization for adverse events.
There were four deaths during the study, none
classified as related to study drug. One serious
adverse event (dyspnea) was considered possibly
related to treatment with moxifloxacin; one serious
adverse (upper digestive tract bleeding) was
classified as probably related to treatment with
levofloxacin. There were no significant changes in
vital signs throughout the study, and no significant
between-group differences with respect to clinical
laboratory parameters.Discussion
AECB is a common and debilitating condition that
can be caused by a wide range of bacterial
pathogens. As the conventional microbiological
assessment of etiology and antimicrobial suscept-
ibility are time-consuming and not always reliable,
antimicrobial therapy for this condition is generally
instituted empirically. However, in recent years,
empiric antimicrobial therapy of AECB has been
complicated by the spread of antimicrobial resis-
tance.8,9 Indeed, although b-lactams have tradi-
tionally been the mainstay of therapy for AECB,
resistance has spread rapidly through S. pneumo-
niae, and a high proportion of H. influenzae and of
M. catarrhalis strains now produce b-lactamases,
rendering penicillins inactive.8 In view of this, the
newer macrolides, e.g., clarithromycin and azi-
thromycin, have become more widely used for
management of AECB. However, macrolide resis-
tance is now also well established among S.
pneumoniae, and the activity of these agents
against H. influenzae, one of the most important
AECB pathogens, is marginal.8
In this study we compared the efficacy and safety
of a 5-day course of the fluoroquinolone moxiflox-
acin with that of a 7-day course of levofloxacin. A
high rate of clinical success was observed in bothtreatment groups. Within 1–3 days of finishing
therapy, clinical success was achieved in 91% of
patients treated with short-course (5-day) moxi-
floxacin and 94% of patients treated with levoflox-
acin for 7 days in the per-protocol population.
Similarly at the test of cure visit, 7–14 days after
finishing therapy, the short-course regimen of
moxifloxacin proved to be as effective clinically
as the 7-day levofloxacin regimen, with continued
clinical resolution reported in over 90% of per-
protocol patients in both groups. These rates are
similar to those reported previously by Hautamaki
and colleagues10 in a US study of similar design (93%
and 94% clinical success for moxifloxacin and
levofloxacin, respectively, at test of cure). Other
comparative trials have also shown a 5-day course
of moxifloxacin to be as effective clinically as
standard regimens of azithromycin and clarithro-
mycin, and possibly superior to co-amoxiclav 7
days11–13. The shorter duration of the moxifloxacin
course is also likely to have benefits in terms of
improved compliance (i.e., increased likelihood
that the patient will complete the entire recom-
mended treatment course), which in theory may
also reduce the opportunity for development of
resistant organisms. Shorter-course therapy may
also offer tolerability benefits.
In vitro and in vivo studies have shown that
moxifloxacin has a broad spectrum of activity
covering a wide range of bacterial pathogens
implicated in community-acquired respiratory tract
infections.6,14 In the present study, moxifloxacin
demonstrated potent in vitro activity against the
range of causative pathogens isolated at the pre-
therapy visit. Against Streptococcus species, such
as S. pneumoniae, the MICs for moxifloxacin were
approximately 2–3 dilutions lower than those for
levofloxacin, indicating that moxifloxacin was the
more potent of the two agents. Against Gram-
negative pathogens, the two agents showed com-
parable in vitro activity. Including the present
study, five double-blind and five open-label studies
evaluating the efficacy of moxifloxacin in 414,000
patients with AECB have been reported so
far.10–13,15–18 Analysis of these studies gives mean
overall clinical and bacteriologic success rates for
moxifloxacin in AECB of 95% and 92%, respectively.
Moxifloxacin and levofloxacin had very similar
adverse event profiles in the present study, with
nausea being the most common drug-related event
in both groups. Therapy was generally well toler-
ated, and the rate of premature discontinuation of
study drug because of adverse events was very low
in both groups (approximately 2%).
In conclusion, this study has shown that a
5-day course of moxifloxacin 400mg once daily is
ARTICLE IN PRESS
Moxifloxacin against exacerbations of brochitis 1511clinically and bacteriologically equivalent to a
7-day course of levofloxacin 400mg once daily in
the treatment of patients with AECB. The shorter
treatment duration with moxifloxacin may have
compliance advantages over other currently used
therapies in the ‘real-life’ clinical setting.Acknowledgements
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